🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

U.S., China Advance Discussions On Pact To Accelerate Cancer Drug Trials forbes.com/sites/russellf…

Wall Street Journal headline writers folks… The Wall Street Journal—seriously, wtf. wsj.com/articles/are-t…

Home - Cure4Cancer cure4cancerglobal.org

WOW! This is the view from the The George Washington bridge running from Manhattan, New York to New Jersey. - This is all stemming from Central Canada, where wildfires are burning in the provinces of Ontario and Quebec. - In total there are 211 reported wildfires burning in

Language remains a barrier to diversity in cancer clinical trials. Report nature shows that pts with limited English proficiency were much less likely to participate in academic trials as compared to industry studies (which have funding for translation). nature.com/articles/s4158…

Diversity in clinical trials in Europe and the US: a review of a pharmaceutical company’s data collection, reporting, and interpretation of race and ethnicity - Annals of Oncology. Data from 286 BMS hematology & oncology trials annalsofoncology.org/article/S0923-…

Bristol Myers Squibb - Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics investors.bms.com/iframes/press-…

Simultaneous NEJM publication of DeLLphi-301 study after #ESMO23 presentation by Dr. Luis Paz-Ares. This DLL3 bispecific shows tremendous promise in previously treated #SCLC and represents an exciting new strategy for this disease. nejm.org/doi/full/10.10…

#ESMO23 Great discussion on ramucirumab + osimertinib by Dr. Yilong Wu. Why was the US study by Dr. Xiuning Le MD PhD significantly positive (PFS HR 0.55) but the Japanese study negative? Exposure (14.2m vs 140d), schedule (q3w vs q2w). Any bias from seeing control arm less frequently?

#ESMO23 Dr. Luis Paz-Ares presents TROPION-Lung05: datopotamab deruxtecan (TROP2 ADC) in NSCLC with an actionable genomic alteration and prior targeted therapy and chemotherapy. Dose 6mg/kg q3w. Heavily pretreated group here. 57% #EGFR, 25% #ALK, also ROS1, RET, BRAF.

What an impactful Presidential symposium at #ESMO23. THREE NEJM articles already: selpercatinib in #RET NSCLC, selpercatinib in medullary thyroid, and amivantamab with chemo in #EGFR exon 20. Congrats to Prof. Caicun Zhou - two first-author NEJM papers in one day!

Stop by poster 698P #ESMO23 for a look at HPN328, the DLL3 T-cell engager you don’t want to miss!

First-year #pharmacy residents are invited to apply for MSK's second-year residency program by January 2, 2024. MSK is hosting multiple information sessions before then, including one this Wednesday 10/25. Visit bit.ly/3rXjhcx to learn more.

Registration is OPEN for the #ATOPPSummit in St. Louis this June! Join us for a dynamic exchange of ideas, problem-solving sessions, and networking opportunities. Visit atoppsummit.com to register! #oncopharm #TwitteRx

2023 FDA approvals nature.com/articles/d4157…

Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours astrazeneca.com/media-centre/p…

T-DXd is highly active for HER2-mutant NSCLC. Could it work also in other tumors with HER2-mutations? In DESTINY-PT01, 102 pts with solid tumors harboring activating HER2 mutations received T-DXd. ORR 29%, PFS 5.4 months. Highest activity in breast cancer. thelancet.com/journals/lanon…

(1/2) Dr. Bob Li, thoracic oncologist from MSK, & international colleagues published the first tumor-agnostic study of a HER2-directed antibody-drug conjugate in patients w/ solid tumors harboring activating HER2 mutations in The Lancet Oncology in April 2024: bit.ly/44wSPFt

US FDA accepts for priority review BLA of zenocutuzumab (HER2/3 bispecific antibody) for patients with #NRG1 fusion NSCLC or pancreatic cancer. Fusions in NRG1 (neuregulin) are rare but important, can be missed by DNA NGS, best detected with RNA-seq. ir.merus.nl/news-releases/…

Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC - Merus ir.merus.nl/news-releases/…